Lundbeck, officially known as H. Lundbeck A/S, is a global pharmaceutical company headquartered in Denmark (DK). Founded in 1915, Lundbeck has established itself as a leader in the neuroscience sector, focusing on the treatment of brain disorders such as depression, schizophrenia, and Alzheimer's disease. With a strong presence in Europe, North America, and Asia, the company is dedicated to improving the lives of patients through innovative therapies. Lundbeck's core products include a range of unique medications that address complex neurological conditions, setting them apart in a competitive market. The company has achieved notable milestones, including the development of several breakthrough treatments that have significantly impacted patient care. Renowned for its commitment to research and development, Lundbeck continues to strengthen its position as a key player in the global pharmaceutical industry.
How does Lundbeck's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Lundbeck's score of 86 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2025, Lundbeck reported total greenhouse gas emissions of approximately 106,700,000 kg CO2e for Scope 1, 2, and 3 emissions combined. Specifically, their emissions breakdown included about 10,670,000 kg CO2e from Scope 1, 2,887,000 kg CO2e from Scope 2, and a significant 65,528,000 kg CO2e from Scope 3. This represents a total of approximately 13,557,000 kg CO2e for Scope 1 and 2 combined. For 2024, Lundbeck's emissions were approximately 11,547,000 kg CO2e for Scope 1, 3,526,000 kg CO2e for Scope 2, and 66,039,000 kg CO2e for Scope 3, totalling around 15,073,000 kg CO2e for Scope 1 and 2. In 2023, the company reported higher emissions, with Scope 1 at about 20,191,000 kg CO2e, Scope 2 at 7,173,000 kg CO2e, and Scope 3 at 124,338,000 kg CO2e, leading to a combined Scope 1 and 2 total of approximately 27,364,000 kg CO2e. Lundbeck has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050. Near-term targets include a 42% reduction in absolute Scope 1 and 2 emissions by 2029 from a 2019 baseline, and a 25% reduction in Scope 3 emissions over the same period. Long-term goals target a 90% reduction in all scopes by 2050. Additionally, Lundbeck's Transition Plan aims to utilise 100% renewable electricity for all EU sites by 2025, further demonstrating their commitment to sustainability. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect their dedication to addressing climate change within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 6,626,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,317,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lundbeck is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
